Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Fulcrum Therapeutics (NASDAQ:FULC), a clinical-stage biopharmaceutical company, has scheduled a conference call and webcast for July 29, 2025, at 8:00 a.m. ET to present topline results from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease.
The presentation will feature distinguished speakers including Dr. Sheinei Alan from the Inova Fairfax Adult Sickle Cell Program and Dr. Wally Smith from the VCU Adult Sickle Cell Program, who will join Fulcrum's management team to discuss the findings.
Fulcrum Therapeutics (NASDAQ:FULC), una società biofarmaceutica in fase clinica, ha programmato una conference call e una webcast per il 29 luglio 2025, alle 8:00 ET per presentare i risultati preliminari del coorte da 12 mg dello studio di Fase 1b PIONEER su pociredir nella malattia falciforme.
La presentazione vedrà la partecipazione di relatori di rilievo come il Dott. Sheinei Alan del Programma per Adulti con Anemia Falciforme di Inova Fairfax e il Dott. Wally Smith del Programma per Adulti con Anemia Falciforme di VCU, che si uniranno al team dirigenziale di Fulcrum per discutere i risultati.
Fulcrum Therapeutics (NASDAQ:FULC), una compañía biofarmacéutica en etapa clínica, ha programado una llamada de conferencia y webcast para el 29 de julio de 2025 a las 8:00 a.m. ET para presentar los resultados preliminares del grupo de dosis de 12 mg del ensayo de Fase 1b PIONEER de pociredir en la enfermedad de células falciformes.
La presentación contará con destacados ponentes, incluyendo al Dr. Sheinei Alan del Programa de Células Falciformes para Adultos de Inova Fairfax y al Dr. Wally Smith del Programa de Células Falciformes para Adultos de VCU, quienes se unirán al equipo directivo de Fulcrum para discutir los hallazgos.
Fulcrum Therapeutics (NASDAQ:FULC)는 임상 단계 바이오제약 회사로서 2025년 7월 29일 오전 8시(동부 표준시)에 포시레디르의 겸상적혈구병 대상 1b상 PIONEER 시험의 12mg 투여군 주요 결과를 발표하는 컨퍼런스 콜 및 웹캐스트를 예정하고 있습니다.
발표에는 Inova Fairfax 성인 겸상적혈구 프로그램의 Dr. Sheinei Alan과 VCU 성인 겸상적혈구 프로그램의 Dr. Wally Smith 등 저명한 연사들이 참여하며, Fulcrum 경영진과 함께 연구 결과를 논의할 예정입니다.
Fulcrum Therapeutics (NASDAQ:FULC), une société biopharmaceutique en phase clinique, a programmé une conférence téléphonique et un webcast pour le 29 juillet 2025 à 8h00 ET afin de présenter les résultats principaux de la cohorte à 12 mg de l'essai de phase 1b PIONEER de pociredir dans la drépanocytose.
La présentation réunira des intervenants de renom, notamment le Dr Sheinei Alan du programme drépanocytose adulte d'Inova Fairfax et le Dr Wally Smith du programme drépanocytose adulte de VCU, qui rejoindront l'équipe de direction de Fulcrum pour discuter des résultats.
Fulcrum Therapeutics (NASDAQ:FULC), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, hat eine Telefonkonferenz und Webcast für den 29. Juli 2025 um 8:00 Uhr ET angesetzt, um die Hauptergebnisse der 12 mg Dosisgruppe der Phase-1b-Studie PIONEER mit Pociredir bei Sichelzellerkrankung vorzustellen.
Die Präsentation wird von renommierten Referenten begleitet, darunter Dr. Sheinei Alan vom Inova Fairfax Adult Sickle Cell Program und Dr. Wally Smith vom VCU Adult Sickle Cell Program, die sich mit dem Managementteam von Fulcrum zusammenschließen, um die Ergebnisse zu diskutieren.
- None.
- None.
CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, July 29, 2025 beginning at 8:00 a.m. ET to present topline results from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Members of Fulcrum management will be joined by Dr. Sheinei Alan, Director of the Inova Fairfax Adult Sickle Cell Program, and Assistant Professor at UVA School of Medicine Inova Campus, and Dr. Wally Smith, Director at the VCU Adult Sickle Cell Program and Florence Neal Cooper Smith Professor of Sickle Cell Disease at Virginia Commonwealth University.
To register for this event, please click here or visit the “Events and Presentations” section of Fulcrum’s website. A replay will be available on Fulcrum’s website following the event.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
About Pociredir
Pociredir is an investigational oral small-molecule inhibitor of Embryonic Ectoderm Development (EED) that was discovered using Fulcrum’s proprietary discovery technology. Inhibition of EED leads to potent downregulation of key fetal globin repressors, including BCL11A, thereby causing an increase in fetal hemoglobin (HbF). Pociredir is being developed for the treatment of SCD. Initial data in SCD demonstrated proof-of-concept and achieved absolute levels of HbF increases associated with potential overall patient benefit. In clinical trials conducted prior to the clinical hold, which was lifted by the FDA in August 2023, pociredir was demonstrated to be generally well-tolerated in people with SCD with up to three months of exposure, with no serious treatment-related adverse events reported. Pociredir has been granted FDA Fast Track designation and Orphan Drug Designation for the treatment of SCD. To learn more about these trials please visit ClinicalTrials.gov.
About Sickle Cell Disease
SCD is a genetic disorder of the red blood cells caused by a mutation in the HBB gene. This gene encodes a protein that is a key component of hemoglobin, a protein complex whose function is to transport oxygen in the body. The result of the mutation is less efficient oxygen transport and the formation of red blood cells that have a sickle shape. These sickle shaped cells are much less flexible than healthy cells and can block blood vessels or rupture cells. People with SCD typically suffer from serious clinical consequences, which may include anemia, pain, infections, stroke, heart disease, pulmonary hypertension, kidney failure, liver disease, and reduced life expectancy.
Contact:
Alan Musso
Chief Financial Officer
amusso@fulcrumtx.com
FAQ
When will Fulcrum Therapeutics (FULC) present the PIONEER trial results for pociredir?
What is the focus of Fulcrum's PIONEER trial presentation?
Who are the key speakers at Fulcrum's PIONEER trial presentation?
How can investors access Fulcrum's PIONEER trial results presentation?
